$CNTACentessa Pharmaceuticals plc

📅 Upcoming

🕒 Recent(90d)

News

• Takeda leads wave of orexin drugs with potential to upend narcolepsy market
  The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
  biospace · 1d ago
• Takeda approval ushers in new wave of sleep drugs
  An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.
  biopharma_dive · 14d ago
• Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
  Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.
  biospace · 15d ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 15d ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 28d ago
• Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
  The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
  biopharma_dive · 1mo ago
• Lilly buys non-opioid pain drugmaker 4E
  It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
  biopharma_dive · 2mo ago
• Lilly, Gilead lead pharma’s M&A boom
  Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
  biopharma_dive · 3mo ago